Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Case Study: Successful Strategic Planning in Life Sciences with EvoLV

Nov 27, 2025

Introduction to Strategic Planning in Life Sciences

The life sciences industry is continuously evolving, with new innovations and challenges emerging regularly. Effective strategic planning is crucial for companies to stay competitive and drive growth. EvoLV, a leader in the field, has demonstrated a remarkable approach to strategic planning, setting a benchmark for others in the sector.

EvoLV's strategic planning process is a blend of innovation, foresight, and meticulous execution. This case study explores their successful journey, providing insights that other life sciences companies can emulate.

strategic planning

Understanding EvoLV's Approach

EvoLV employs a comprehensive approach to strategic planning, focusing on several key areas. Their strategy is built on a foundation of thorough market analysis, stakeholder engagement, and forward-thinking leadership. This ensures that they are not only meeting current demands but are also poised to capitalize on future opportunities.

A critical component of EvoLV's strategy is their emphasis on sustainability and ethical practices. By integrating these values into their plans, they ensure long-term success and positive impact on society.

Market Analysis and Research

Market analysis is at the core of EvoLV's strategic planning. They invest heavily in research to understand market trends, customer needs, and competitive landscapes. This data-driven approach enables them to make informed decisions and stay ahead of the competition.

market research

Stakeholder Engagement

EvoLV places a strong emphasis on engaging with stakeholders, including employees, customers, and partners. By fostering open communication and collaboration, they ensure that all voices are heard and considered in the planning process.

This inclusive approach not only enhances decision-making but also strengthens relationships, leading to increased trust and loyalty among stakeholders.

Leadership and Innovation

The leadership at EvoLV is committed to fostering an innovative culture. By encouraging creative thinking and risk-taking, they empower their teams to explore new ideas and solutions. This culture of innovation is a driving force behind their strategic success.

innovation teamwork

Implementation and Execution

One of the standout aspects of EvoLV's strategic planning is their focus on execution. They understand that a well-crafted plan is only as good as its implementation. To ensure successful execution, they set clear objectives, allocate resources efficiently, and monitor progress rigorously.

Their use of technology and automation tools further streamlines processes, enabling them to adapt quickly to changing circumstances.

Measuring Success

Measuring success is crucial for continuous improvement. EvoLV uses a combination of quantitative and qualitative metrics to evaluate the effectiveness of their strategic initiatives. This continuous feedback loop allows them to refine their strategies and achieve better outcomes over time.

business success

Conclusion

EvoLV's approach to strategic planning in the life sciences industry serves as a powerful example of how thoughtful, data-driven strategies can lead to success. By focusing on market analysis, stakeholder engagement, leadership, and execution, they have set a standard for others to follow.

As the industry continues to evolve, companies that adopt similar strategic planning practices will be well-positioned to thrive in the competitive landscape.